Clinical Trial Search

Primary: Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA) — 9 percentage of participants

Primary: Median Absolute Change From Baseline in Electromyographic (EMG) Peak Amplitude of the Bicep/Tricep — 22.310; 7.010; 16.070; 10.055 percentage of MVC — p=0.002

Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012

Primary: Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -6.8; -8.9 score on a scale — p=0.1768

Primary: Number of Patients Enrolled. — 58 Participants

Primary: Overall Survival — 89.2 percentage of participants

Primary: Number of Participants With Adverse Events (AEs): Phase I & II — 13; 13; 5; 11 Participants

Primary: Change in FEV1 Percentage Predicted From Baseline — 11.8; 8.8 percentage of predicted

Primary: Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months — 9; 8; 4 participants

Primary: Treatment-Emergent Adverse Event Frequency by Treatment - Number of Patients Reporting Events — 10; 8; 14; 10 Participants

Primary: Change From Baseline In Hemoglobin At Week 24 — 7.94; 10.33; 2.39 g/dL

Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio

Primary: Overall Response Rate — 1; 1; 3; 1 Participants

Primary: Pain Intensity at Rest Evaluated Using a 0-100 mm VAS — 9.6; 16.9; 18.4; 8.1 score on a scale

Primary: Temperature Burden — 37.8; 37.7 Temperature in degrees Celsius